|
ヤノ シュウヤ
Shuya Yano
矢野 修也 所属 川崎医科大学 医学部 臨床医学 臨床腫瘍学 職種 臨床助教11年 |
|
| 論文種別 | 総説 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment. |
| 掲載誌名 | 正式名：International journal of molecular sciences 略 称：Int J Mol Sci ISSNコード：14220067/14220067 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 22(2),pp.879 |
| 著者・共著者 | Yano Shuya, Tazawa Hiroshi, Kishimoto Hiroyuki, Kagawa Shunsuke, Fujiwara Toshiyoshi, Hoffman Robert M |
| 担当区分 | 筆頭著者,責任著者 |
| 発行年月 | 2021/01 |
| 概要 | Oncolytic virotherapy is one of the most promising, emerging cancer therapeutics. We generated three types of telomerase-specific replication-competent oncolytic adenovirus: OBP-301; a green fluorescent protein (GFP)-expressing adenovirus, OBP-401; and Killer-Red-armed OBP-301. These oncolytic adenoviruses are driven by the human telomerase reverse transcriptase (hTERT) promoter; therefore, they conditionally replicate preferentially in cancer cells. Fluorescence imaging enables visualization of invasion and metastasis in vivo at the subcellular level; including molecular dynamics of cancer cells, resulting in greater precision therapy. In the present review, we focused on fluorescence imaging applications to develop precision targeting for oncolytic virotherapy. Cell-cycle imaging with the fluorescence ubiquitination cell cycle indicator (FUCCI) demonstrated that combination therapy of an oncolytic adenovirus and a cytotoxic agent could precisely target quiescent, chemoresistant cancer stem cells (CSCs) based on decoying the cancer cells to cycle to S-phase by viral treatment, thereby rendering them chemosensitive. Non-invasive fluorescence imaging demonstrated that complete tumor resection with a precise margin, preservation of function, and prevention of distant metastasis, was achieved with fluorescence-guided surgery (FGS) with a GFP-reporter adenovirus. A combination of fluorescence imaging and laser ablation using a KillerRed-protein reporter adenovirus resulted in effective photodynamic cancer therapy (PDT). Thus, imaging technology and the designer oncolytic adenoviruses may have clinical potential for precise cancer targeting by indicating the optimal time for administering therapeutic agents; accurate surgical guidance for complete resection of tumors; and precise targeted cancer-specific photosensitization. |
| DOI | 10.3390/ijms22020879 |
| PMID | 33477279 |